Form 4: BioLife Solutions CEO Sells Shares Under 10b5-1 Plan

BioLife Solutions CEO, Roderick de Greef, sold 46,896 shares of common stock at $23.43 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Roderick de Greef, the President and CEO of BioLife Solutions Inc., sold 46,896 shares of common stock on October 31, 2024.
• The shares were sold at a price of $23.43 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan.
• The trading plan was adopted on October 19, 2023.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, de Greef directly owns 414,958 shares of BioLife Solutions stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to a pre-planned stock sale by the CEO. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like BioLife Solutions.
• Similar filings are regularly made by executives at companies such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR), which are also involved in life sciences and biotechnology.
• The volume of shares sold and the price are within the typical range for such transactions, and the use of a 10b5-1 plan is a standard method for managing insider sales.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, Roderick de Greef, insider trading, stock sale, Form 4, 10b5-1 plan, executive compensation